Academic Journal
The alcohol cue-exposure paradigm as a screening tool for alcohol use disorder medication development: A critical review.
| Τίτλος: | The alcohol cue-exposure paradigm as a screening tool for alcohol use disorder medication development: A critical review. |
|---|---|
| Συγγραφείς: | Kirsch DE; Department of Psychology, University of California, Los Angeles, Los Angeles, California, USA., Grodin EN; Department of Psychology, University of California, Los Angeles, Los Angeles, California, USA.; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, USA., Leggio L; Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse Intramural Research Program and National Institute on Alcohol Abuse and Alcoholism Division of Intramural Clinical and Biological Research, National Institutes of Health, Baltimore, Maryland, USA., McKee SA; Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA., Meredith LR; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA., Mereish EH; Department of Psychology, University of Maryland, College Park, Maryland, USA., Miranda R Jr; Department of Psychiatry and Human Behavior, Brown University, Providence, Rhode Island, USA., Nieto SJ; Department of Psychology, University of California, Los Angeles, Los Angeles, California, USA., O'Malley SS; Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA., Schacht JP; Department of Psychiatry, University of Colorado School of Medicine, Aurora, Colorado, USA., Ray LA; Department of Psychology, University of California, Los Angeles, Los Angeles, California, USA.; Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, California, USA. |
| Πηγή: | Alcohol, clinical & experimental research [Alcohol Clin Exp Res (Hoboken)] 2025 Nov; Vol. 49 (11), pp. 2412-2426. Date of Electronic Publication: 2025 Sep 29. |
| Τύπος έκδοσης: | Journal Article; Review |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Wiley Periodicals Country of Publication: United States NLM ID: 9918609780906676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2993-7175 (Electronic) Linking ISSN: 29937175 NLM ISO Abbreviation: Alcohol Clin Exp Res (Hoboken) Subsets: MEDLINE |
| Imprint Name(s): | Original Publication: Hoboken, NJ : Wiley Periodicals, [2023]- |
| Ιατρικοί όροι (MeSH): | Alcoholism*/drug therapy , Alcoholism*/diagnosis , Alcoholism*/psychology , Drug Development*/methods , Cues*, Humans ; Craving |
| Περίληψη: | The alcohol cue-exposure paradigm has a long and rich history in alcohol use disorder (AUD) research, contributing to the identification of risk factors, the recognition of craving as a core symptom, the understanding of AUD neurobiology, and the development of both pharmacological and behavioral treatments. The goal of this review was to evaluate the utility of the alcohol cue-exposure paradigm as a screening tool for AUD medication development and to provide recommendations for refinement of the paradigm. First, we review evidence supporting the predictive validity and clinical applicability of the alcohol cue-exposure paradigm. Second, we examine current practices in implementing the paradigm in AUD pharmacotherapy studies. Third, we highlight several areas for refinement and offer recommendations for the implementation of this paradigm. Finally, we outline key conclusions and actionable future directions. In summary, while the alcohol cue-exposure paradigm has an established foundation in the study of AUD pharmacotherapies, its future success hinges on a concerted effort to refine and standardize protocols and validate outcome measures in large-scale studies. Addressing these priorities could accelerate the development and regulatory approval of novel treatments for AUD. (© 2025 The Author(s). Alcohol, Clinical and Experimental Research published by Wiley Periodicals LLC on behalf of Research Society on Alcohol.) |
| References: | JCI Insight. 2024 Dec 20;9(24):. (PMID: 39704175) Neuropsychopharmacology. 2009 Apr;34(5):1198-208. (PMID: 18563062) J Neurosci. 2023 Mar 1;43(9):1600-1613. (PMID: 36657973) Annu Rev Clin Psychol. 2010;6:591-606. (PMID: 20192791) Psychopharmacology (Berl). 2008 Sep;200(1):141-50. (PMID: 18604601) Alcohol Clin Exp Res. 2020 Jul;44(7):1431-1443. (PMID: 32363592) Psychopharmacology (Berl). 2024 Aug;241(8):1679-1689. (PMID: 38613685) Alcohol Res Health. 1999;23(3):174-8. (PMID: 10890812) Transl Psychiatry. 2021 Jun 12;11(1):355. (PMID: 34120149) Eur Arch Psychiatry Clin Neurosci. 2021 Aug;271(5):915-927. (PMID: 33884495) Addiction. 2000 Aug;95 Suppl 2:S129-44. (PMID: 11002908) J Stud Alcohol. 1994 Jul;55(4):487-94. (PMID: 7934057) JAMA. 2023 Nov 7;330(17):1653-1665. (PMID: 37934220) Psychopharmacology (Berl). 2001 Apr;155(1):27-34. (PMID: 11374333) Addict Biol. 2013 Jan;18(1):121-33. (PMID: 22574861) Prog Brain Res. 2016;224:401-18. (PMID: 26822368) Am J Drug Alcohol Abuse. 2017 Mar;43(2):186-196. (PMID: 27439453) Cochrane Database Syst Rev. 2010 Dec 08;(12):CD001867. (PMID: 21154349) JAMA Intern Med. 2014 Jan;174(1):70-7. (PMID: 24190578) Neuropsychopharmacology. 2021 Jul;46(8):1414-1420. (PMID: 33558678) Drugs. 2022 Feb;82(3):251-274. (PMID: 35133639) Addict Biol. 2022 Jan;27(1):e13069. (PMID: 34132011) Eur Neuropsychopharmacol. 2018 Nov;28(11):1206-1216. (PMID: 30217552) JAMA. 2006 May 3;295(17):2003-17. (PMID: 16670409) Alcohol Clin Exp Res. 2019 Jun;43(6):1263-1272. (PMID: 31099903) Alcohol Clin Exp Res. 2014 Nov;38(11):2754-62. (PMID: 25421512) Nat Protoc. 2022 Mar;17(3):567-595. (PMID: 35121856) Alcohol Clin Exp Res (Hoboken). 2024 Sep;48(9):1772-1783. (PMID: 38960894) Addict Biol. 2017 Nov;22(6):1515-1527. (PMID: 27411969) Addict Biol. 2014 Sep;19(5):941-54. (PMID: 23489253) Alcohol Clin Exp Res. 1999 Aug;23(8):1386-94. (PMID: 10470982) Mol Psychiatry. 2020 Feb;25(2):461-475. (PMID: 29728704) Drug Alcohol Depend. 2024 Mar 1;256:111123. (PMID: 38367535) Addiction. 2000 Aug;95 Suppl 2:S189-210. (PMID: 11002914) ACS Chem Neurosci. 2015 Apr 15;6(4):522-5. (PMID: 25734247) J Clin Psychopharmacol. 2012 Oct;32(5):661-5. (PMID: 22926600) Pharmacol Biochem Behav. 2013 Feb;103(4):784-91. (PMID: 23262301) Psychopharmacology (Berl). 2014 Sep;231(18):3799-807. (PMID: 24647921) Am J Drug Alcohol Abuse. 2020;46(1):131-138. (PMID: 31295037) J Abnorm Psychol. 1987 May;96(2):122-6. (PMID: 3584660) Clin Psychol Rev. 2022 Feb;91:102110. (PMID: 34864497) Addict Behav. 1990;15(2):137-46. (PMID: 2343787) Am J Psychiatry. 2023 Jun 1;180(6):445-453. (PMID: 36987598) Alcohol Alcohol. 2025 Jan 19;60(2):. (PMID: 39829301) Annu Rev Pharmacol Toxicol. 2016;56:299-322. (PMID: 26514207) Addict Biol. 2020 Jan;25(1):e12717. (PMID: 30748046) Neuropsychopharmacology. 2000 May;22(5):480-92. (PMID: 10731623) Alcohol Clin Exp Res. 2018 Sep;42(9):1612-1622. (PMID: 29969156) Neuroimage. 2011 May 1;56(1):61-8. (PMID: 21316465) Addict Behav. 2024 Aug;155:108028. (PMID: 38640885) Biol Psychiatry. 2011 Jun 1;69(11):1060-6. (PMID: 21292243) Trials. 2014 Apr 23;15:139. (PMID: 24755011) J Consult Clin Psychol. 1994 Jun;62(3):620-6. (PMID: 8063989) Alcohol Clin Exp Res. 1999 Feb;23(2):195-203. (PMID: 10069545) Alcohol Clin Exp Res (Hoboken). 2025 Nov;49(11):2412-2426. (PMID: 41017297) Clin Psychol Rev. 2009 Aug;29(6):519-34. (PMID: 19577831) Addict Biol. 2009 Jan;14(1):73-83. (PMID: 18855801) Psychopharmacology (Berl). 2025 Jan;242(1):149-160. (PMID: 39102049) Nat Rev Rheumatol. 2018 Jun;14(6):354-362. (PMID: 29760435) J Stud Alcohol. 1994 Mar;55(2):224-9. (PMID: 8189743) J Neurosci Res. 2021 Jan;99(1):309-323. (PMID: 32333417) Am J Drug Alcohol Abuse. 2025 Jan 02;51(1):14-30. (PMID: 39868972) Eur Neuropsychopharmacol. 2007 Jul;17(8):558-66. (PMID: 17379484) Alcohol Clin Exp Res. 2012 Feb;36(2):351-60. (PMID: 21919922) Transl Psychiatry. 2017 Apr 25;7(4):e1108. (PMID: 28440812) Addiction. 2000 Aug;95 Suppl 2:S229-36. (PMID: 11002917) Alcohol Clin Exp Res. 2012 Jun;36(6):972-83. (PMID: 22309888) JAMA. 2014 May 14;311(18):1889-900. (PMID: 24825644) J Abnorm Psychol. 1997 May;106(2):243-50. (PMID: 9131844) Alcohol Clin Exp Res (Hoboken). 2023 Sep;47(9):1629-1645. (PMID: 37423771) Neuropsychopharmacology. 2017 Dec;42(13):2640-2653. (PMID: 28409564) World J Cardiol. 2014 May 26;6(5):245-52. (PMID: 24891935) J Neural Transm (Vienna). 2000;107(6):721-30. (PMID: 10943912) Neurosci Biobehav Rev. 2021 Sep;128:294-310. (PMID: 34171325) JAMA Psychiatry. 2024 Apr 01;81(4):414-425. (PMID: 38324323) Biol Sex Differ. 2022 Jun 27;13(1):34. (PMID: 35761351) Neuropsychopharmacology. 2022 Oct;47(11):1953-1960. (PMID: 35523943) Alcohol Clin Exp Res (Hoboken). 2024 Dec;48(12):2352-2363. (PMID: 39623527) Arch Intern Med. 2007 Apr 9;167(7):716-21. (PMID: 17420431) Psychopharmacology (Berl). 2009 Jul;205(1):53-62. (PMID: 19319508) Arch Gen Psychiatry. 2008 Apr;65(4):466-75. (PMID: 18391135) Neurobiol Stress. 2019 Feb 08;10:100149. (PMID: 30949562) Neurobiol Stress. 2024 Aug 10;32:100668. (PMID: 39252986) Psychopharmacology (Berl). 2021 May;238(5):1291-1302. (PMID: 30788529) J Clin Invest. 2015 Aug 3;125(8):3193-7. (PMID: 26121746) |
| Grant Information: | K24 AA025704 United States AA NIAAA NIH HHS; K01 AA029712 United States AA NIAAA NIH HHS; K24 AA026326 United States AA NIAAA NIH HHS; K24AA025704 United States AA NIAAA NIH HHS; K24AA026326 United States AA NIAAA NIH HHS |
| Contributed Indexing: | Keywords: addiction; alcohol use disorder; craving; cue reactivity; medications |
| Entry Date(s): | Date Created: 20250929 Date Completed: 20251121 Latest Revision: 20260307 |
| Update Code: | 20260307 |
| PubMed Central ID: | PMC12638288 |
| DOI: | 10.1111/acer.70170 |
| PMID: | 41017297 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 2993-7175 |
|---|---|
| DOI: | 10.1111/acer.70170 |